Difference between revisions of "Smith DC, et al. Clin. Cancer Res. (2014) cited as Ref 595 in DOI: 10.1038/s41392-020-0110-5 (Q9858)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 20, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English) | ||
| Property / title: A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Smith DC, et al. Clin. Cancer Res. (2014) cited as Ref 595 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Smith DC
0 references
2014
0 references
Clin. Cancer Res.
0 references
20
0 references
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English)
0 references
